PDL BioPharma Reports 2020 Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PDL BioPharma (PDLI) Misses Q2 EPS by 21c, Revenues Beat
August 6, 2020 5:54 PM EDTPDL BioPharma (NASDAQ: PDLI) reported Q2 EPS of ($0.11), $0.21 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $5.21 million versus the consensus estimate of $1.5 million.
"I am pleased with the significant progress we have made over the past... More
